TR199900191T2 - (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses. - Google Patents

(S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.

Info

Publication number
TR199900191T2
TR199900191T2 TR1999/00191T TR9900191T TR199900191T2 TR 199900191 T2 TR199900191 T2 TR 199900191T2 TR 1999/00191 T TR1999/00191 T TR 1999/00191T TR 9900191 T TR9900191 T TR 9900191T TR 199900191 T2 TR199900191 T2 TR 199900191T2
Authority
TR
Turkey
Prior art keywords
improved process
synthesis
dihydroxybutyric acid
esters
protected esters
Prior art date
Application number
TR1999/00191T
Other languages
English (en)
Turkish (tr)
Inventor
Elliott Jacks Thomas
Eugene Butler Donald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR199900191T2 publication Critical patent/TR199900191T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/03Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
TR1999/00191T 1996-07-29 1997-07-01 (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses. TR199900191T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2236996P 1996-07-29 1996-07-29

Publications (1)

Publication Number Publication Date
TR199900191T2 true TR199900191T2 (xx) 1999-04-21

Family

ID=21809241

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00191T TR199900191T2 (xx) 1996-07-29 1997-07-01 (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.

Country Status (17)

Country Link
US (1) US5998633A (enExample)
EP (1) EP0915866B1 (enExample)
JP (1) JP2000515882A (enExample)
KR (1) KR100447370B1 (enExample)
CN (1) CN1093126C (enExample)
AT (1) ATE215078T1 (enExample)
AU (1) AU3515497A (enExample)
CO (1) CO4950542A1 (enExample)
DE (1) DE69711391T2 (enExample)
DK (1) DK0915866T3 (enExample)
ES (1) ES2176756T3 (enExample)
HU (1) HU226465B1 (enExample)
IL (1) IL127058A (enExample)
PT (1) PT915866E (enExample)
TR (1) TR199900191T2 (enExample)
WO (1) WO1998004543A1 (enExample)
ZA (1) ZA976705B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0915866T3 (da) * 1996-07-29 2002-06-10 Warner Lambert Co Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
KR100332703B1 (ko) * 1998-07-24 2002-08-27 삼성정밀화학 주식회사 광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
CN1160468C (zh) * 1998-07-24 2004-08-04 三星精密化学株式会社 制备光学纯(s)-3,4-二羟基丁酸衍生物的方法
US6713290B2 (en) 1998-07-24 2004-03-30 Samsung Fine Chemicals Co., Ltd. Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
US6235930B1 (en) * 1999-03-31 2001-05-22 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
AU776613B2 (en) 1999-12-17 2004-09-16 Pfizer Science And Technology Ireland Limited A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
CA2391357C (en) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
JP4598917B2 (ja) * 2000-04-28 2010-12-15 ダイセル化学工業株式会社 ラクトンの製造方法
KR100645665B1 (ko) 2000-07-27 2006-11-13 에스케이 주식회사 (s)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1728785A1 (en) 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
MXPA03010266A (es) * 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
SK802004A3 (en) * 2001-07-06 2004-10-05 Teva Pharma Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
BR0215602A (pt) * 2002-02-25 2004-12-07 Biocon Ltd ésteres de boronato
GB0211716D0 (en) 2002-05-22 2002-07-03 Phoenix Chemicals Ltd Process
ATE368661T1 (de) * 2002-08-06 2007-08-15 Warner Lambert Co Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
CA2499655A1 (en) * 2002-09-18 2004-04-01 Sk Corporation Continuous process for the production of optically pure (s)-.beta.-hydroxy-.gamma.-butyrolactone
AU2003263031A1 (en) * 2002-09-20 2004-04-08 Diversa Corporation Chemoenzymatic methods for the synthesis of statins and stain intermediates
US6713639B1 (en) 2002-10-28 2004-03-30 Council Of Scientific And Industrial Research Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
EP1615883A1 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US7232920B2 (en) * 2003-04-22 2007-06-19 Biocon Process for stereoselective reduction of β-ketoesters
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CN1852894A (zh) * 2003-09-17 2006-10-25 沃尼尔·朗伯有限责任公司 [R-(R*, R*)]-2-(4-氟苯基) -β,δ-二羟基-5-(1-甲基乙基) -3-苯基-4-[(苯基氨基)羰基] -1 H-吡咯-1-庚酸的结晶形式
WO2005068642A2 (en) 2003-10-01 2005-07-28 Board Of Trustees Operating Michigan State University Bacterial synthesis of 1,2,4-butanetriol enantiomers
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
EP2540704B1 (en) 2004-05-05 2019-07-03 Pfizer Products Inc. Benethamine salt forms of atorvastatin
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
DE602006013815D1 (de) * 2005-05-31 2010-06-02 Kowa Co Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
DK1957452T3 (da) * 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
US20110165641A1 (en) * 2006-03-31 2011-07-07 The Board Of Trustees Of Michigan State University Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
CN101512004A (zh) * 2006-07-19 2009-08-19 密歇根州州立大学托管委员会 D-1,2,4-丁三醇的微生物合成
KR100850558B1 (ko) 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
JP2009256316A (ja) 2008-03-28 2009-11-05 Daicel Chem Ind Ltd β−ヒドロキシ−γ−ブチロラクトンの製造方法
CN101337906B (zh) * 2008-08-15 2012-06-27 河南豫辰精细化工有限公司 一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN106588689A (zh) * 2016-12-15 2017-04-26 河南豫辰药业股份有限公司 一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
CN112939901B (zh) * 2021-02-09 2023-05-09 中国科学院福建物质结构研究所 一种α-羟基-γ-丁内酯的制备方法
CN114195670B (zh) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 一种阿托伐他汀母核m4的精制方法
CN117447350A (zh) * 2023-10-26 2024-01-26 河南豫辰药业股份有限公司 一种阿托伐他汀m4有机废物综合再利用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2710688B2 (ja) * 1990-10-09 1998-02-10 鐘淵化学工業株式会社 4―ブロモ―3―ヒドロキシ酪酸エステル誘導体の製造法
CA2049536C (en) * 1991-05-13 1999-07-06 Rawle I. Hollingsworth Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof
JP3351563B2 (ja) * 1992-12-03 2002-11-25 鐘淵化学工業株式会社 3−ヒドロキシ酪酸誘導体の製造法
DK0915866T3 (da) * 1996-07-29 2002-06-10 Warner Lambert Co Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre

Also Published As

Publication number Publication date
JP2000515882A (ja) 2000-11-28
ATE215078T1 (de) 2002-04-15
DK0915866T3 (da) 2002-06-10
ZA976705B (en) 1998-02-10
EP0915866B1 (en) 2002-03-27
IL127058A (en) 2001-07-24
WO1998004543A1 (en) 1998-02-05
CO4950542A1 (es) 2000-09-01
CN1093126C (zh) 2002-10-23
KR20000029648A (ko) 2000-05-25
CN1223647A (zh) 1999-07-21
HK1020728A1 (en) 2000-05-19
HUP9904348A2 (hu) 2000-04-28
PT915866E (pt) 2002-07-31
DE69711391D1 (de) 2002-05-02
US5998633A (en) 1999-12-07
HUP9904348A3 (en) 2004-03-01
DE69711391T2 (de) 2002-11-07
IL127058A0 (en) 1999-09-22
ES2176756T3 (es) 2002-12-01
KR100447370B1 (ko) 2004-09-08
AU3515497A (en) 1998-02-20
HU226465B1 (en) 2008-12-29
EP0915866A1 (en) 1999-05-19

Similar Documents

Publication Publication Date Title
TR199900191T2 (xx) (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
RU95114376A (ru) Нитроэфиры, обладающие фармакологической активностью, и способ их получения
HUP0100845A3 (en) Hydroxamid acid derivatives as matrix metalloprotease(mmp) inhibitors, process for producing them and pharmaceutical compositions containing them
TR199600792A2 (tr) Dihaloazolopirimidinlerin hazirlanmasina yönelik proses.
ID19926A (id) Proses untuk produksi asam tereftalat murni
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
TR27976A (tr) Antibalistik olarak etkili maddelerin plazmaya maruz birakilmasi icin bir islem.
AU6617596A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, their preparation process, their use as medicaments, and pharmaceutical compositions containing them
HUP0002921A3 (en) Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
HUP0002853A3 (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
ZA979756B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
NO960826L (no) Anvendelse av enzymer fra krill i forstoffer
IN187760B (enExample)
TR200000624T2 (tr) Bir enzimin etkinliğinin arttırılması ile ilgili bir yöntem.
ID29219A (id) (1-fenasi-3-fenil-3-piperidiletil): turunan-turunan piperidin, proses untuk memperolehnya dan komposisi-komposisi farmasi
FI945328A7 (fi) Laitos sähköenergian tuottamiseksi polttoaineista, erityisesti biogeenisistä polttoaineista
ES542835A0 (es) Procedimiento de preparar un antigeno relacionado con el ligamento glicosidico,derivado de celulas de cancer.
ID27785A (id) Proses pembuatan asam n-fosfonometil iminodiasetat
CA2294158A1 (en) Natural antitumor or antiviral substances and use of the same
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
TR200003351T2 (tr) Paroksetin içeren yeni formülasyon
DE69013786D1 (de) Brennstoffzellengenerator.
HUP0004386A3 (en) Methylenebisphosphonic acid derivatives, process for producing them and medicaments containing the same as active agent
DE68903410D1 (de) Einrichtung zum auslesen von elektrischen ladungen, die durch halbleitersubstrat-photodioden geliefert werden.